Background: The pandemic of COVID19 presents itself, to date, as the greatest
health challenge of this century. Central physiopathology involves an infectious
respiratory disease caused by SARSCoV2 capable of causing cardiovascular
complications in the most severe cases, including thromboembolism. Objective: This
study aims to characterize the clinical and laboratory profile of hospitalized patients
with documented thrombosis/pulmonary thromboembolism during COVID19 infection.
Methods: Medical records of patients hospitalized in three tertiary care medical
centers in the capital city of Pará, Brazil, with deep vein thrombosis or pulmonary
thromboembolism diagnosed by imaging were reviewed. Relevant epidemiological,
comorbidities, and laboratory data were analyzed. Results: The incidence of venous
thromboembolism was 1.3%, ranging from 0.6% to 2.25% in the different centers.
Mean values for age, Creactive protein, Ddimer, body mass index, and length of stay
were 46.35 years, 143.23 mg/l, 4.12 µg/ml, 27.65 kg/m², and 50.18 days, respectively.
No significant correlations (pvalue <0.05) were found between any of the variables
studied and the presence of thrombosis or pulmonary thromboembolism. Conclusion:
There seems to be no relationship between the presence of venous thromboembolism
and the presence of some prevalent endocrinemetabolic comorbidities or laboratory
patterns in COVID19 infection. Individual risk factors may significantly influence the
thrombotic and thromboembolic risk. Important limitations in data including the
possibility of underdiagnosis and incomplete completion of medical records may
confound the results. Some public health referral services need more infrastructural
support. More studies should be conducted involving more accurate data.
|
